Lipoproteins for therapeutic delivery: recent advances and future opportunities
The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time...
Gespeichert in:
| Veröffentlicht in: | Therapeutic delivery 2018-03, Vol.9 (4), p.257-268 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 268 |
|---|---|
| container_issue | 4 |
| container_start_page | 257 |
| container_title | Therapeutic delivery |
| container_volume | 9 |
| creator | Raut, Sangram Dasseux, Jean-Louis Sabnis, Nirupama A Mooberry, Linda Lacko, Andras |
| description | The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed. |
| doi_str_mv | 10.4155/tde-2017-0122 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2216557581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216557581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-f90f119d656250847112f46d01c2796fe0be7bfd9f9cbf3372f2513ae583ce473</originalsourceid><addsrcrecordid>eNp1kM9PwyAUx4nRODN39GpIPFeBQinezOKvZMkueiYtPCLL1lagS_bfy9LpzXfhkXz4vscHoRtK7jkV4iFZKBihsiCUsTN0xQinRUVIfX7qhVJkhhYxbkguTigX7BLNmOJKKKau0Hrlh34IfQLfRez6gNMXhGaAMXmDLWz9HsLhEQcw0CXc2H3TGYi46Sx2YxoD4H4Y-pDGzicP8RpduGYbYXE65-jz5flj-Vas1q_vy6dVYUpJU-EUcZQqW4mKCVJzSSlzvLKEGiZV5YC0IFtnlVOmdWUpmWOClg2IujTAZTlHd1Nu3v17hJj0ph9Dl0dqxmglhBQ1zVQxUSb0MQZwegh-14SDpkQfDepsUB8N6qPBzN-eUsd2B_aP_vWVATUB09-j8ZB16OmWX3jjO_gn_AehAH_G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216557581</pqid></control><display><type>article</type><title>Lipoproteins for therapeutic delivery: recent advances and future opportunities</title><source>MEDLINE</source><source>PubMed Central</source><creator>Raut, Sangram ; Dasseux, Jean-Louis ; Sabnis, Nirupama A ; Mooberry, Linda ; Lacko, Andras</creator><creatorcontrib>Raut, Sangram ; Dasseux, Jean-Louis ; Sabnis, Nirupama A ; Mooberry, Linda ; Lacko, Andras</creatorcontrib><description>The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.</description><identifier>ISSN: 2041-5990</identifier><identifier>EISSN: 2041-6008</identifier><identifier>DOI: 10.4155/tde-2017-0122</identifier><identifier>PMID: 29495929</identifier><language>eng</language><publisher>England: Future Science Ltd</publisher><subject>Animals ; Antineoplastic Agents - administration & dosage ; Apolipoprotein A-I - administration & dosage ; Apolipoproteins ; Atherosclerosis - drug therapy ; Biocompatibility ; Biomimetic Materials - chemistry ; Cancer ; cancer therapy ; Cell growth ; Cholesterol ; Clinical Trials as Topic ; discoidal nanoparticles ; Drug Compounding - methods ; Drug Compounding - trends ; drug delivery ; Drug Delivery Systems - methods ; Drug Delivery Systems - trends ; Drug dosages ; Drug resistance ; Efficiency ; HDL ; Humans ; Hydrophobicity ; LDL ; Lipids ; Lipoproteins ; Lipoproteins - chemistry ; Medical research ; Metabolism ; Metabolites ; Metastasis ; Nanoparticles ; Nanoparticles - chemistry ; Neoplasms - drug therapy ; Peptides ; Phospholipids - administration & dosage ; Physiology ; Proteins ; Recombinant Proteins - administration & dosage ; rHDL ; Theranostic Nanomedicine - methods ; Theranostic Nanomedicine - trends ; Therapeutic applications ; Tumors</subject><ispartof>Therapeutic delivery, 2018-03, Vol.9 (4), p.257-268</ispartof><rights>2018 Newlands Press</rights><rights>Copyright Newlands Press Mar 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-f90f119d656250847112f46d01c2796fe0be7bfd9f9cbf3372f2513ae583ce473</citedby><cites>FETCH-LOGICAL-c371t-f90f119d656250847112f46d01c2796fe0be7bfd9f9cbf3372f2513ae583ce473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29495929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raut, Sangram</creatorcontrib><creatorcontrib>Dasseux, Jean-Louis</creatorcontrib><creatorcontrib>Sabnis, Nirupama A</creatorcontrib><creatorcontrib>Mooberry, Linda</creatorcontrib><creatorcontrib>Lacko, Andras</creatorcontrib><title>Lipoproteins for therapeutic delivery: recent advances and future opportunities</title><title>Therapeutic delivery</title><addtitle>Ther Deliv</addtitle><description>The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.</description><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Apolipoprotein A-I - administration & dosage</subject><subject>Apolipoproteins</subject><subject>Atherosclerosis - drug therapy</subject><subject>Biocompatibility</subject><subject>Biomimetic Materials - chemistry</subject><subject>Cancer</subject><subject>cancer therapy</subject><subject>Cell growth</subject><subject>Cholesterol</subject><subject>Clinical Trials as Topic</subject><subject>discoidal nanoparticles</subject><subject>Drug Compounding - methods</subject><subject>Drug Compounding - trends</subject><subject>drug delivery</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Delivery Systems - trends</subject><subject>Drug dosages</subject><subject>Drug resistance</subject><subject>Efficiency</subject><subject>HDL</subject><subject>Humans</subject><subject>Hydrophobicity</subject><subject>LDL</subject><subject>Lipids</subject><subject>Lipoproteins</subject><subject>Lipoproteins - chemistry</subject><subject>Medical research</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metastasis</subject><subject>Nanoparticles</subject><subject>Nanoparticles - chemistry</subject><subject>Neoplasms - drug therapy</subject><subject>Peptides</subject><subject>Phospholipids - administration & dosage</subject><subject>Physiology</subject><subject>Proteins</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>rHDL</subject><subject>Theranostic Nanomedicine - methods</subject><subject>Theranostic Nanomedicine - trends</subject><subject>Therapeutic applications</subject><subject>Tumors</subject><issn>2041-5990</issn><issn>2041-6008</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kM9PwyAUx4nRODN39GpIPFeBQinezOKvZMkueiYtPCLL1lagS_bfy9LpzXfhkXz4vscHoRtK7jkV4iFZKBihsiCUsTN0xQinRUVIfX7qhVJkhhYxbkguTigX7BLNmOJKKKau0Hrlh34IfQLfRez6gNMXhGaAMXmDLWz9HsLhEQcw0CXc2H3TGYi46Sx2YxoD4H4Y-pDGzicP8RpduGYbYXE65-jz5flj-Vas1q_vy6dVYUpJU-EUcZQqW4mKCVJzSSlzvLKEGiZV5YC0IFtnlVOmdWUpmWOClg2IujTAZTlHd1Nu3v17hJj0ph9Dl0dqxmglhBQ1zVQxUSb0MQZwegh-14SDpkQfDepsUB8N6qPBzN-eUsd2B_aP_vWVATUB09-j8ZB16OmWX3jjO_gn_AehAH_G</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Raut, Sangram</creator><creator>Dasseux, Jean-Louis</creator><creator>Sabnis, Nirupama A</creator><creator>Mooberry, Linda</creator><creator>Lacko, Andras</creator><general>Future Science Ltd</general><general>Newlands Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20180301</creationdate><title>Lipoproteins for therapeutic delivery: recent advances and future opportunities</title><author>Raut, Sangram ; Dasseux, Jean-Louis ; Sabnis, Nirupama A ; Mooberry, Linda ; Lacko, Andras</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-f90f119d656250847112f46d01c2796fe0be7bfd9f9cbf3372f2513ae583ce473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Apolipoprotein A-I - administration & dosage</topic><topic>Apolipoproteins</topic><topic>Atherosclerosis - drug therapy</topic><topic>Biocompatibility</topic><topic>Biomimetic Materials - chemistry</topic><topic>Cancer</topic><topic>cancer therapy</topic><topic>Cell growth</topic><topic>Cholesterol</topic><topic>Clinical Trials as Topic</topic><topic>discoidal nanoparticles</topic><topic>Drug Compounding - methods</topic><topic>Drug Compounding - trends</topic><topic>drug delivery</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Delivery Systems - trends</topic><topic>Drug dosages</topic><topic>Drug resistance</topic><topic>Efficiency</topic><topic>HDL</topic><topic>Humans</topic><topic>Hydrophobicity</topic><topic>LDL</topic><topic>Lipids</topic><topic>Lipoproteins</topic><topic>Lipoproteins - chemistry</topic><topic>Medical research</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metastasis</topic><topic>Nanoparticles</topic><topic>Nanoparticles - chemistry</topic><topic>Neoplasms - drug therapy</topic><topic>Peptides</topic><topic>Phospholipids - administration & dosage</topic><topic>Physiology</topic><topic>Proteins</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>rHDL</topic><topic>Theranostic Nanomedicine - methods</topic><topic>Theranostic Nanomedicine - trends</topic><topic>Therapeutic applications</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raut, Sangram</creatorcontrib><creatorcontrib>Dasseux, Jean-Louis</creatorcontrib><creatorcontrib>Sabnis, Nirupama A</creatorcontrib><creatorcontrib>Mooberry, Linda</creatorcontrib><creatorcontrib>Lacko, Andras</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Therapeutic delivery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raut, Sangram</au><au>Dasseux, Jean-Louis</au><au>Sabnis, Nirupama A</au><au>Mooberry, Linda</au><au>Lacko, Andras</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipoproteins for therapeutic delivery: recent advances and future opportunities</atitle><jtitle>Therapeutic delivery</jtitle><addtitle>Ther Deliv</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>9</volume><issue>4</issue><spage>257</spage><epage>268</epage><pages>257-268</pages><issn>2041-5990</issn><eissn>2041-6008</eissn><abstract>The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.</abstract><cop>England</cop><pub>Future Science Ltd</pub><pmid>29495929</pmid><doi>10.4155/tde-2017-0122</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2041-5990 |
| ispartof | Therapeutic delivery, 2018-03, Vol.9 (4), p.257-268 |
| issn | 2041-5990 2041-6008 |
| language | eng |
| recordid | cdi_proquest_journals_2216557581 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Antineoplastic Agents - administration & dosage Apolipoprotein A-I - administration & dosage Apolipoproteins Atherosclerosis - drug therapy Biocompatibility Biomimetic Materials - chemistry Cancer cancer therapy Cell growth Cholesterol Clinical Trials as Topic discoidal nanoparticles Drug Compounding - methods Drug Compounding - trends drug delivery Drug Delivery Systems - methods Drug Delivery Systems - trends Drug dosages Drug resistance Efficiency HDL Humans Hydrophobicity LDL Lipids Lipoproteins Lipoproteins - chemistry Medical research Metabolism Metabolites Metastasis Nanoparticles Nanoparticles - chemistry Neoplasms - drug therapy Peptides Phospholipids - administration & dosage Physiology Proteins Recombinant Proteins - administration & dosage rHDL Theranostic Nanomedicine - methods Theranostic Nanomedicine - trends Therapeutic applications Tumors |
| title | Lipoproteins for therapeutic delivery: recent advances and future opportunities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T11%3A48%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipoproteins%20for%20therapeutic%20delivery:%20recent%20advances%20and%20future%20opportunities&rft.jtitle=Therapeutic%20delivery&rft.au=Raut,%20Sangram&rft.date=2018-03-01&rft.volume=9&rft.issue=4&rft.spage=257&rft.epage=268&rft.pages=257-268&rft.issn=2041-5990&rft.eissn=2041-6008&rft_id=info:doi/10.4155/tde-2017-0122&rft_dat=%3Cproquest_cross%3E2216557581%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216557581&rft_id=info:pmid/29495929&rfr_iscdi=true |